Goodwill and Other Intangible Assets

3 Months Ended

Mar. 27, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS

The following is a rollforward of the Company’s goodwill ($ in millions):

Balance, December 31, 2025	$	43,151
Foreign currency translation and other	(386)
Balance, March 27, 2026	$	42,765

The carrying value of goodwill by segment is summarized as follows ($ in millions):

	March 27, 2026		December 31, 2025
Biotechnology	$	22,999	$	23,313
Life Sciences	12,805		12,856
Diagnostics	6,961		6,982
Total	$	42,765	$	43,151

The Company has not identified any “triggering” events which indicate an impairment of goodwill in the first quarter of 2026. The Company has not identified any impairment triggers that resulted in impairments of intangible assets in the first quarter of 2026. The Company will continue to review goodwill and other intangible assets for impairment when events or changes in circumstances, including evolving market conditions and regulatory environment, indicate related carrying amounts may not be recoverable.

During the three-month period ended March 28, 2025, the Company recorded a $15 million impairment related to a facility in the Biotechnology segment, which was recorded in cost of sales in the accompanying Consolidated Condensed Statements of Earnings.